摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

7-[(4-iodophenoxy)-methyl]-2-nitro-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine | 1263188-41-5

中文名称
——
中文别名
——
英文名称
7-[(4-iodophenoxy)-methyl]-2-nitro-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine
英文别名
7-[(4-iodophenoxy)methyl]-2-nitro-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine
7-[(4-iodophenoxy)-methyl]-2-nitro-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine化学式
CAS
1263188-41-5
化学式
C13H12IN3O4
mdl
——
分子量
401.16
InChiKey
JAHVSZUFIWAMIE-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.9
  • 重原子数:
    21
  • 可旋转键数:
    3
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.31
  • 拓扑面积:
    82.1
  • 氢给体数:
    0
  • 氢受体数:
    5

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    7-[(4-iodophenoxy)-methyl]-2-nitro-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine4-氟苯硼酸(1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride sodium carbonate 作用下, 以 乙醇甲苯 为溶剂, 反应 1.5h, 以91%的产率得到7-{[(4'-fluoro[1,1'-biphenyl]-4-yl)oxy]methyl}-2-nitro-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine
    参考文献:
    名称:
    NITROIMIDAZOOXAZINE AND NITROIMIDAZOOXAZOLE ANALOGUES AND THEIR USES
    摘要:
    当前的发明涉及硝基咪唑噁啉和硝基咪唑噁唑类似物,它们的制备方法,以及将这些化合物用作治疗结核分枝杆菌、用作抗结核药物、用作对克氏锥虫或唐氏利什曼原虫具有意外高效的抗原虫药剂,以及用于治疗其他微生物感染的用途。
    公开号:
    US20110028466A1
  • 作为产物:
    描述:
    2-bromo-1-{2-[(2R)-2-methyl-1,4-dioxaspiro[4.5]dec-2-yl]ethyl}-4-nitro-1H-imidazole 在 咪唑盐酸 、 sodium hydride 、 对甲苯磺酸三苯基膦偶氮二甲酸二乙酯 作用下, 以 四氢呋喃甲醇乙醇N,N-二甲基甲酰胺 为溶剂, 反应 447.8h, 生成 7-[(4-iodophenoxy)-methyl]-2-nitro-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine
    参考文献:
    名称:
    7-Substituted 2-Nitro-5,6-dihydroimidazo[2,1-b][1,3]oxazines: Novel Antitubercular Agents Lead to a New Preclinical Candidate for Visceral Leishmaniasis
    摘要:
    Within a backup program for the clinical investigational agent pretomanid (PA-824), scaffold hopping from delamanid inspired the discovery of a novel class of potent antitubercular agents that unexpectedly possessed notable utility against the kinetoplastid disease visceral leishmaniasis (VL). Following the identification of delamanid analogue DNDI-VL-2098 as a VL preclinical candidate, this structurally related 7 substituted 2-nitro-5,6-dihydroimidazo [2,1-b][1,3]oxazine class was further explored, seeking efficacious backup compounds with improved solubility and safety. Commencing with a biphenyl lead, bioisosteres formed by replacing one phenyl by pyridine or pyrimidine showed improved solubility and potency, whereas more hydrophilic side chains reduced VL activity. In a Leishmania donovani mouse model, two racemic phenylpyridines (71 and 93) were superior, with the former providing >99% inhibition at 12.5 mg/kg (b.i.d., orally) in the Leishmania infantum hamster model. Overall, the 7R enantiomer of 71 (79) displayed more optimal efficacy, pharmacokinetics, and safety, leading to its selection as the preferred development candidate.
    DOI:
    10.1021/acs.jmedchem.7b00034
点击查看最新优质反应信息

文献信息

  • [EN] NITROIMIDAZOOXAZINE AND NITROIMIDAZOOXAZOLE ANALOGUES AND THEIR USES<br/>[FR] ANALOGUES DE NITRO-IMIDAZO-OXAZINE ET DE NITRO-IMIDAZO-OXAZOLE ET LEURS UTILISATIONS
    申请人:GLOBAL ALLIANCE FOR TB DRUG DEV
    公开号:WO2011014776A1
    公开(公告)日:2011-02-03
    The current invention pertains to nitroimidazooxazine and nitroimidazooxazole analogues, their methods of preparation, and uses of the compounds as treatment for Mycobacterium tuberculosis, for use as anti-tubercular drugs, for use as anti-protozoal agents with unexpectedly high potency against Trypanosoma cruzi or Leishmania donovani, and for the treatment of other microbial infections.
    本发明涉及硝基咪唑氧杂环丙烷和硝基咪唑氧杂环咪唑类似物,它们的制备方法以及将这些化合物用作治疗结核分枝杆菌的药物,用作抗结核药物,用作抗原虫药物,对Trypanosoma cruzi或Leishmania donovani具有意外高效的药物,并用于治疗其他微生物感染。
  • Nitroimidazooxazine and nitroimidazooxazole analogues and their uses
    申请人:Global Alliance for TB Drug Development
    公开号:US08293734B2
    公开(公告)日:2012-10-23
    The current invention pertains to nitroimidazooxazine and nitroimidazooxazole analogues, their methods of preparation, and uses of the compounds as treatment for Mycobacterium tuberculosis, for use as anti-tubercular drugs, for use as anti-protozoal agents with unexpectedly high potency against Trypanosoma cruzi or Leishmania donovani, and for the treatment of other microbial infections.
    本发明涉及硝基咪唑氧噁啉和硝基咪唑氧唑类似物,其制备方法以及将这些化合物用作治疗结核分枝杆菌的药物、用作抗结核药物、用作抗原虫药物,对Trypanosoma cruzi或Leishmania donovani具有意外的高效性,并用于治疗其他微生物感染。
  • NITROIMIDAZOOXAZINE ANALOGUES AND THEIR USES
    申请人:Global Alliance For Tb Drug Development
    公开号:EP2459570B1
    公开(公告)日:2014-12-24
  • US8293734B2
    申请人:——
    公开号:US8293734B2
    公开(公告)日:2012-10-23
查看更多